基本信息
views: 334
Career Trajectory
Bio
My interests at UCI will be to incorporate novel and targeted therapies in the treatment of upper aero-digestive tract malignancies. I am especially interested in Lung cancer in never-smokers who harbor specific genetic alterations: activating mutations in the epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) translocation-fusion. I currently am the Principal Investigator in clinical trials that investigate second generation EGFR tyrosine kinase inhibitors (TKIs), acquired resistance to first generation EGFR TKIs, and inhibitor to the ALK (Crizotinib). Additionally, I have international collaboration with investigators in Asia to investigate the difference in lung cancer according to ethnicity, and the role of environmental tobacco smoke (ETS) and the occurrence in the genetic alterations in lung cancer patients who are never-smokers.
Research Interests
Papers共 449 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Faustine X Luo,Sai-Hong Ignatius Ou
Lung Cancer: Targets and Therapy (2024): 69-73
Lung Cancer (Auckland, N.Z.) (2024): 81-85
The Lancet Respiratory Medicine (2024)
Sai-Hong Ignatius Ou,Xiuning Le,Misako Nagasaka,Thanyanan Reungwetwattana, Myung-Ju Ahn,Darren W T Lim, Edgardo S Santos,Elaine Shum,Sally C M Lau,Jii Bum Lee, Antonio Calles, Fengying Wu,
Lung Cancer (Auckland, NZ) (2024): 87-114
Med (New York, N.Y.)no. 6 (2024): 645-645
EXPERT OPINION ON INVESTIGATIONAL DRUGSno. 2 (2024): 79-84
Translational lung cancer researchno. 5 (2024): 1047-1060
Lung Cancer (Auckland, N.Z.) (2024): 19-27
Clinical Pharmacokineticsno. 2 (2024): 171-182
Load More
Author Statistics
#Papers: 446
#Citation: 23872
H-Index: 74
G-Index: 147
Sociability: 8
Diversity: 0
Activity: 5
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn